Clinical Trials & Pipeline
News & Events
Mirna is a clinical-stage biopharmaceutical and immuno-oncology company developing a broad pipeline of leading microRNA-based oncology therapeutics, the first to be tested in cancer patients.
LEARN MORE ABOUT US
MRX34, Mirna’s lead product candidate, is the first microRNA mimic to enter clinical testing.
LEARN MORE ABOUT OUR CLINICAL TRIALS AND PIPELINE
November 19, 2014
Mirna Presents Interim Phase 1 Data on First-in-Class microRNA-34 mimic, MRX34, at EORTC-NCI-AACR Symposium
September 26, 2014
Mirna Announces Scientific Publication that Outlines a Combinatorial microRNA Approach in Preclinical Lung Cancer Model
VIEW ALL NEWS
© 2014 Mirna Therapeutics, Inc. All Rights Reserved.